Bayesian Estimation of Methotrexate Pharmacokinetic Parameters and Area Under the Curve in Children and Young Adults with Localised Osteosarcoma
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 41 (13), 1095-1104
- https://doi.org/10.2165/00003088-200241130-00006
Abstract
Methotrexate is the most efficient anticancer drug in osteosarcoma. It requires individual exposure monitoring because of the high doses used, its wide interpatient pharmacokinetic variability and the existence of demonstrated relationships between efficacy, toxicity and serum drug concentrations. To develop a maximum a posteriori (MAP) Bayesian estimator able to predict individual pharmacokinetic parameters and exposure indices such as area under the curve (AUC) for methotrexate from a few blood samples, in order to prevent toxicity and facilitate further studies of the relationships between efficacy and exposure. Methotrexate population pharmacokinetics were estimated by a retrospective analysis of concentration data from 40 children and young adults by using the nonparametric expectation maximisation method NPEM. A linear two-compartment model with elimination from the central compartment was assumed. Individual pharmacokinetic parameters and AUC were subsequently estimated in 30 other young patients, using MAP Bayesian estimation as implemented in two programs, ADAPT II and an inhouse program Winphar®. The pharmacokinetic parameters used in the model were the volume of the central compartment (V1) and the transfer constants (k10, k12 and k21). The mean values (with percentage coefficient of variation) obtained were: 18.24L (54.1%) and 0.41 (42.3%), 0.0168 (68.7%), and 0.1069 (61.3%) h-1, respectively. Bayesian forecasting enabled nonbiased estimation of AUC and systemic clearance using a schedule with two sampling times (6 and 24 hours after the beginning of the infusion) and either program. Collection of a third sample at 4 hours improved the precision. The Bayesian adaptive method developed herein allows accurate estimation of individual exposure to methotrexate and can easily be used in clinical practice.Keywords
This publication has 29 references indexed in Scilit:
- Adaptive Control Methods for the Dose Individualisation of Anticancer AgentsClinical Pharmacokinetics, 2000
- Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approachFundamental & Clinical Pharmacology, 1999
- Methodological Issues in Pharmacokinetic-Pharmacodynamic ModellingClinical Pharmacokinetics, 1998
- Model-Based, Goal-Oriented, Individualised Drug TherapyClinical Pharmacokinetics, 1998
- Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.JCI Insight, 1996
- Bayesian Estimation and Population Pharmacokinetic Parameters of High Dose Methotrexate in OsteosarcomaClinical Research and Regulatory Affairs, 1993
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaThe New England Journal of Medicine, 1986
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityThe New England Journal of Medicine, 1977
- Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion patternEuropean Journal of Cancer (1965), 1972